Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
DDRGK1 (DDRGK domain containing 1), New evidence suggests that ER stress and mitochondrial dysfunction are closely associated with ROS production. Human DDRGK-containing domain protein 1 (DDRGK1) is a strongly conserved protein coding for the short arm of chromosome 20 (20p13) and localized to peroxisomes, mitochondria, and endoplasmic reticulum.
DDRGK1 Plays a Role in Endoplasmic Reticulum Homeostasis
DDRGK1 has been shown to play an essential role in endoplasmic reticulum homeostasis by regulating the stability of IRE1a, thus suggesting a potential role for DDRGK1 in the maintenance of redox homeostasis. To date, DDRGK1 has mostly been recognized as a substrate for UFMylation, which binds target proteins to ubiquitin fold modification factor 1 (UFM1). Despite its recently demonstrated role in UFMylation-mediated regulation of erythroid progression, spinal chondrodysplasia, and plasma cell development, the mechanisms by which DDRGK1 modulates UFMylation, as well as its other functions, remain largely unknown. Indeed, the identification of proteins interacting with DDRGK1 using label-free quantitative proteomics suggests that DDRGK1 is involved in the regulation of protein folding, stabilization, and trafficking.
DDRGK1 Plays a Role in Cell Growth
Deficiency of DDRGK1 leads to embryonic death in vivo, suggesting that it plays an integral role in cell growth, and most studies consider DDRGK1 to be a cytoprotective protein. However, the function of DDRGK1 in tumorigenesis and development remains controversial. For example, DDRGK1 interacts with and regulates the stability of IkBa, and its absence inhibits tumor cell proliferation. [In addition, by interacting with activation signaling integrator 1 (ASC1), DDRGK1 regulates UFMylation of ASC1 and promotes the development of ER-positive breast cancer. However, DDRGK1 has also been shown to maintain p53 stability and impair colon cancer growth by cooperating with UFM1 and covalently modifying p53. Covalent modification of p53. function in tumors in the absence of further research.
DDRGK1 Plays a Role in Regulating Cellular ROS Accumulation
Due to the fact that ROS are usually upregulated in tumor cells, tumor cells are heavily dependent on the antioxidant system to keep ROS effectively below lethal levels and are more susceptible to any damage that disrupts ROS homeostasis. Novel role for DDRGK1 in regulating the key ROS proteins, which compete with NRF2 for binding to the Kelch-like ECH-associated protein 1 (KEAP1), blocking the initiation of ubiquitin protease-mediated degradation by CUL3, the E3 ligase of NRF2, thereby broadly regulating the antioxidant system. DDRKG1 induced cellular ROS accumulation, leading to apoptosis and attenuation of DOX chemoresistance, which further inhibited tumor formation in vivo. Taken together, these results reveal a critical role for DDRGK1 in the KEAP1/NRF2/ROS pathway, which is instrumental in osteosarcoma development and chemoresistance.
The stability of NRF2 is critical for ROS homeostasis and is mainly degraded via the ubiquitin-proteasome pathway. KEAP1 acts as an adapter to link NRF2 to the CUL3-based E3 ligase. Hence, disrupting the interaction between NRF2 and KEAP1 or CUL3 may affect the degradation of NRF2. For instance, iASPP competes with NRF2 for KEAP1 binding through the DLT motif, resulting in reduced ubiquitination of NRF2. Similar to these studies, we also found that DDRGK1 can compete for binding to the Kelch domain of KEAP1, thereby blocking the interaction of NRF2 with CUL3 and inhibiting NRF2 degradation. ddrgk1 deletion induces NRF2 protein degradation and reduces the downstream expression of antioxidant proteins, which in turn induces ROS production.
Figure 1. Regulatory functions of DDRGK1 in the maintenance of ER homoeostasis.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.